A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Part of paid clinical trials in Denver, Colorado.

Sponsor
Climb Bio, Inc.
Study ID
NCT07096843
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Primary Membranous Nephropathy

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • budoprutug — DRUG
    Single IV dose of study product on Day 1, Day 15, Day 169 and Day 183

Study Details

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN

Key Dates

Start date
Aug 25, 2025
Status verified
Apr 2026
Primary completion
Oct 31, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
45 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1: Dose Level A
  • Experimental: Cohort 2: Dose Level B
  • Experimental: Cohort 3: Dose Level C

Primary Outcome Measure

Incidence of Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Up to Week 48 ]

Central Contacts

Locations (8)

FacilityCityStateZIPSite coordinators
Climb Bio Investigative Site #110DenverColorado80220-
Climb Bio Investigative Site #105OrlandoFlorida32086-
Climb Bio Investigative Site #108AtlantaGeorgia30342-
Climb Bio Investigative Site #106IndianapolisIndiana46268-
Climb Bio Investigative Site #101Clifton ParkNew York12065-
Climb Bio Investigative Site #102PhiladelphiaPennsylvania19104-
Climb Bio Investigative Site #103El PasoTexas79932-
Climb Bio Investigative Site #104ShermanTexas75092-

Find similar trials in Denver, CO

By research site
Climb Bio Investigative· Denver, COClimb Bio Investigative· Orlando, FLClimb Bio Investigative· Atlanta, GAClimb Bio Investigative· Indianapolis, INClimb Bio Investigative· Clifton Park, NYClimb Bio Investigative· Philadelphia, PA

Related Studies